ArticleACR open rheumatology2025

Impact of Scleroderma-Associated Autoantibodies on Clinical Outcome Assessments: Post Hoc Analysis From a Randomised, Double-blind, Placebo-controlled, Phase 3 Trial of Tocilizumab in Scleroderma.

Basmah Al Dulaijan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.